The same study reported that a CD48 antagonist (neutralizing monoclonal antibody [mAb]) induced a significant reduction in SA adherence and its intracellular localization in CD48-deficient (CD48-/-) mice, which could be used to treat allergy (72). This evidence concerns the gene CD48 and allergic disease.